論文 - 永田 賢治
-
Kameda T., Shide K., Yamaji T., Kamiunten A., Sekine M., Hidaka T., Kubuki Y., Sashida G., Aoyama K., Yoshimitsu M., Abe H., Miike T., Iwakiri H., Tahara Y., Yamamoto S., Hasuike S., Nagata K., Iwama A., Kitanaka A., Shimoda K.
Genomics Data 4 102 - 108 2015年6月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Genomics Data
© 2015 The Authors. Myeloproliferative neoplasms (MPNs) are clinically characterized by the chronic overproduction of differentiated peripheral blood cells and the gradual expansion of malignant intramedullary/extramedullary hematopoiesis. In MPNs mutations in JAK2 MPL or CALR are detected mutually exclusive in more than 90% of cases [1,2]. Mutations in them lead to the abnormal activation of JAK/STAT signaling and the autonomous growth of differentiated cells therefore they are considered as "driver" gene mutations. In addition to the above driver gene mutations mutations in epigenetic regulators such as TET2 DNMT3A ASXL1 EZH2 or IDH1/2 are detected in about 5%-30% of cases respectively [3] . Mutations in TET2 DNMT3A EZH2 or IDH1/2 commonly confer the increased self-renewal capacity on normal hematopoietic stem cells (HSCs) but they do not lead to the autonomous growth of differentiated cells and only exhibit subtle clinical phenotypes [4,6-8,5]. It was unclear how mutations in such epigenetic regulators influenced abnormal HSCs with driver gene mutations how they influenced the disease phenotype or whether a single driver gene mutation was sufficient for the initiation of human MPNs. Therefore we focused on JAK2V617F and loss of TET2-the former as a representative of driver gene mutations and the latter as a representative of mutations in epigenetic regulators-and examined the influence of single or double mutations on HSCs (Lineage < sup > - < /sup > Sca-1 < sup > + < /sup > c-Kit < sup > + < /sup > cells (LSKs)) by functional analyses and microarray whole-genome expression analyses [9]. Gene expression profiling showed that the HSC fingerprint genes [10] was statistically equally enriched in TET2-knockdown-LSKs but negatively enriched in JAK2V617F-LSKs compared to that in wild-type-LSKs. Double-mutant-LSKs showed the same tendency as JAK2V617F-LSKs in terms of their HSC fingerprint genes but the expression of individual genes differed between the two groups. Among 245 HSC fingerprint genes 100 were more highly expressed in double-mutant-LSKs than in JAK2V617F-LSKs. These altered gene expressions might partly explain the mechanisms of initiation and progression of MPNs which was observed in the functional analyses [9]. Here we describe gene expression profiles deposited at the Gene Expression Omnibus (GEO) under the accession number GSE62302 including experimental methods and quality control analyses.
-
インターフェロンによる精神症状発現の予測 気質・性格特性の関与 (共著) 査読あり
直野慶子、安部 博史、武田 龍一郎、岩切 久芳、蓮池 悟、永田 賢治、下田 和哉、石田 康：
精神医学 2015年6月
記述言語：日本語 掲載種別：研究論文（学術雑誌）
-
Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms. (共著) 査読あり
Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Hidaka T, Kubuki Y, Sashida G,Aoyama K, Yoshimitsu M, Abe H, Miike T, Iwakiri H, Tahara Y, Yamamoto S, Hasuike S, Nagata K, Iwama At, Kitanaka A, Shimoda K
Genomics Data. 2015年6月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
12年前から宮崎県に存続している遺伝子型3型E型肝炎ウイルスによるE型急性肝炎の2症例―1例での急性末梢性顔面神経麻痺の合併―
中村 仁彦, 楠元 寿典, 落合 俊雅, 川越 富夫, 田井 博, 松岡 均, 中野 達徳, 永田 賢治, 下田 和哉, 岡本 宏明
日本消化機病學會雜誌. 乙 112 ( 8 ) 1533 - 1541 2015年
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：The Japanese Society of Gastroenterology
宮崎県内で同時期に2例のE型急性肝炎症例を経験した．2例に交友関係，共通の生活歴はなかった．両症例のE型肝炎ウイルス（HEV）株は，遺伝子配列の解析から近縁ではあるが同一株ではなく，感染源は異なると考えられた．2例のHEV株はともに12年前に同県内の飼育ブタから検出された遺伝子型3型株の子孫と考えられ，このウイルスが宮崎県内で存続していることが証明された．1例は急性末梢性顔面神経麻痺を合併した．
-
Ito K., Yotsuyanagi H., Yatsuhashi H., Karino Y., Takikawa Y., Saito T., Arase Y., Imazeki F., Kurosaki M., Umemura T., Ichida T., Toyoda H., Yoneda M., Mita E., Yamamoto K., Michitaka K., Maeshiro T., Tanuma J., Tanaka Y., Sugiyama M., Murata K., Masaki N., Mizokami M., Imai Y., Yamada N., Takahashi H., Ishii K., Nomura H., Nishida J., Mikami S., Kitamura T., Tsubota A., Shimada N., Ishikawa T., Ueno Y., Ohno T., Orito E., Suzuki M., Takagi H., Tomita E., Takashi K., Mizuta T., Mine T., Kang J., Hirano K., Tsubouchi H., Nozaki A., Sakai A., Nishiguchi S., Tamori A., Hagiwara S., Nakazawa T., Sata M., Kamoshida T., Takahashi A., Kakizaki S., Kobayashi Y., Sasaki S., Ikegami T., Hiasa Y., Nagata K., Kubota T., Mitsui H., Yamamoto N., Tsuge M., Sato S., Ito Y., Sato W., Uchida S., Tada Y., Mizuochi T., Furusho N., Hige S.
Hepatology 59 ( 1 ) 89 - 97 2014年1月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Hepatology
© 2013 by the American Association for the Study of Liver Diseases. The proportion of patients who progress to chronicity following acute hepatitis B (AHB) varies widely worldwide. Moreover, the association between viral persistence after AHB and hepatitis B virus (HBV) genotypes in adults remains unclear. A nationwide multicenter study was conducted throughout Japan to evaluate the influence of clinical and virological factors on chronic outcomes in patients with AHB. For comparing factors between AHB patients with viral persistence and those with self-limited infection, 212 AHB patients without human immunodeficiency virus (HIV) coinfection were observed in 38 liver centers until serum hepatitis B surface antigen (HBsAg) disappeared or a minimum of 6 months in cases where HBsAg persisted. The time to disappearance of HBsAg was significantly longer for genotype A patients than that of patients infected with non-A genotypes. When chronicity was defined as the persistence of HBsAg positivity for more than 6 or 12 months, the rate of progression to chronicity was higher in patients with genotype A, although many cases caused by genotype A were prolonged cases of AHB, rather than chronic infection. Multivariate logistic regression analysis revealed only genotype A was independently associated with viral persistence following AHB. A higher peak level of HBV DNA and a lower peak of alanine aminotransferase (ALT) levels were characteristics of AHB caused by genotype A. Treatment with nucleotide analogs (NAs) did not prevent progression to chronic infection following AHB overall. Subanalysis suggested early NA initiation may enhance the viral clearance. Conclusion: Genotype A was an independent risk factor for progression to chronic infection following AHB. Our data will be useful in elucidating the association between viral persistence after AHB, host genetic factors, and treatment with NAs in future studies.
DOI： 10.1002/hep.26635
-
KAWANO Noriaki, HASUIKE Satoru, IWAKIRI Hisayoshi, NAKAMURA Kenichi, OZONO Yoshinori, KUSUMOTO Hisanori, NAGATA Kenji, KIKUCHI Ikuko, YOSHIDA Shuro, KURIYAMA Takuro, YAMASHITA Kiyoshi, MURANAKA Takahiro, KAWAGUCHI Takumi, SATA Michio, OKAMURA Takashi, UEDA Akira, SHIMODA Kazuya
Journal of clinical and experimental hematopathology 53 ( 2 ) 151 - 155 2013年8月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：The Japanese Society for Lymphoreticular Tissue Research
Portal vein thrombosis is a rare, aggressive andlife-threatening complication of liver cirrhosis (LC). Eltrombopag is effective for the treatment of chronic hepatitis with thrombocytopenia, andportal vein thrombosis at this time has rarely been reported. We describe the case of a 78-year-old woman who suffered from LC due to hepatitis C viral infection. The patient developed immune thrombocytopenic purpura (ITP) that was diagnosed on the basis of nasal bleeding, progressive severe thrombocytopenia, elevation of platelet-associatedIgG (PAIgG), no response to the transfusion of platelets andno abnormal findings on bone marrow biopsy. Although we first administered prednisolone (0.5 mg/kg/day), there was no recovery of platelet function and the nasal bleeding persisted. Subsequently, we administered eltrombopag for refractory ITP at a dose of 12.5 mg/day, and the thrombocytopenia gradually improved. Fifty-four days after the start of eltrombopag therapy, she developedportal vein thrombosis. Eltrombopag was stoppedimmed iately, andantithrombin III was administeredfor prophylaxis against further portal vein thrombosis. Despite these treatments, there were subsequent deep vein and pulmonary artery thromboses. We then administered heparin for recanalization of the thrombi. One month after the initiation of heparin, there was recanalization as well as improvements of the portal vein, deep vein and pulmonary artery thromboses. There was no further thrombosis progression after switching from heparin to warfarin therapy. Our case suggests that eltrombopag may increase the risk of portal vein thrombosis ; therefore, this drug must be used carefully in the treatment of ITP in patients with LC due to hepatitis C viral infection. [<I>J Clin Exp Hematop 53(2) : 151-155, 2013</I>]
DOI： 10.3960/jslrt.53.151
-
膜性腎症の治療経過中に発症した de novo B 型肝炎の1例
大園 芳範, 蓮池 悟, 永田 賢治, 山田 優里, 土持 舞衣, 中村 憲一, 白土 明美, 楠元 寿典, 岩切 久芳, 佐藤 祐二, 藤元 昭一, 北村 和雄, 鮫島 直樹, 下田 和哉
肝臓 54 ( 1 ) 74 - 80 2013年1月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：The Japan Society of Hepatology
症例は75歳，男性．特発性膜性腎症に対し免疫抑制療法を施行されていた．治療開始11カ月後に肝障害が出現し当科入院．膜性腎症診断時のHBs抗原陰性，HBs抗体陰性，HBc抗体陽性であり既往感染例と考えられたが，肝障害出現時にHBs抗原陽転化を認めたため，de novo B型肝炎と診断した．HBV-DNAは9.1 logcopies/mLと上昇しており，核酸アナログ製剤の内服を開始した．以後，トランスアミナーゼ，HBV-DNAともに漸減し，重症化・劇症化することなく経過した．de novo B型肝炎の基礎疾患として本症例のような腎疾患の報告は少なく，文献的考察を加えて報告する．<br>
DOI： 10.2957/kanzo.54.74
-
TET2 is essential for survival and hematopoietic stem cell homeostasis
Shide K., Kameda T., Shimoda H., Yamaji T., Abe H., Kamiunten A., Sekine M., Hidaka T., Katayose K., Kubuki Y., Yamamoto S., Miike T., Iwakiri H., Hasuike S., Nagata K., Marutsuka K., Iwama A., Matsuda T., Kitanaka A., Shimoda K.
Leukemia 26 ( 10 ) 2216 - 2223 2012年10月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Leukemia
Ten-Eleven-Translocation 2 (TET2) is an enzyme that catalyzes the conversion of 5-methylcytosine into 5-hydroxymethylcytosine (5-hmC) and thereby alters the epigenetic state of DNA; somatic loss-of-function mutations of TET2 are frequently observed in patients with diverse myeloid malignancies. To study the function of TET2 in vivo, we analyzed Ayu17-449 (TET2 trap ) mice, in which a gene trap insertion in intron 2 of TET2 reduces TET2 mRNA levels to about 20% of that found in wild-type (WT) mice. TET2 trap/trap mice were born at Mendelian frequency but died at a high rate by postnatal day 3, indicating the essential role of TET2 for survival. Loss of TET2 results in an increase in the number of hematopoietic stem cells (HSCs)/progenitors in the fetal liver, and TET2 trap/trap HSCs exhibit an increased self-renewal ability in vivo. In competitive transplantation assays, TET2 trap/trap HSCs possess a competitive growth advantage over WT HSCs. These data indicate that TET2 has a critical role in survival and HSC homeostasis. © 2012 Macmillan Publishers Limited.
DOI： 10.1038/leu.2012.94
-
Umekita K., Miyauchi S., Ueno S., Takajo I., Kusumoto K., Hasuike S., Umekita Y., Tanaka H., Nagata K., Nagatomo Y., Kataoka H., Shimoda K., Okayama A.
Internal Medicine 50 ( 11 ) 1245 - 1249 2011年6月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Internal Medicine
We report a case of rheumatoid arthritis (RA) with autoimmune hepatitis (AIH) and Sjogren syndrome (SjS) that was treated with the tumor necrosis factor (TNF) inhibitor, etanercept (ETN). Both RA activity and transaminase levels improved as a result of treatment. Follow-up liver biopsy showed improvement of hepatitis. Although the efficacy of anti-TNF for RA patients with AIH remains controversial, this case suggests that treatment with ETN may result in a favorable clinical course in a certain subset of patients with RA and AIH. © 2011 The Japanese Society of Internal Medicine.
-
KAWAGUCHI Takumi, KAKUMA Tatsuyuki, YATSUHASHI Hiroshi, WATANABE Hiroshi, SAITSU Hideki, NAKAO Kazuhiko, TAKETOMI Akinobu, OHTA Satoshi, TABARU Akinari, TAKENAKA Kenji, MIZUTA Toshihiko, NAGATA Kenji, KOMORIZONO Yasuji, FUKUIZUMI Kunitaka, SEIKE Masataka, MATSUMOTO Shuichi, MAESHIRO Tatsuji, TSUBOUCHI Hirohito, MURO Toyokichi, INOUE Osami, AKAHOSHI Motoo, SATA Michio
Hepatology research : the official journal of the Japan Society of Hepatology 41 ( 6 ) 564 - 571 2011年6月
記述言語：日本語 掲載種別：研究論文（学術雑誌）
-
Kawaguchi T., Kakuma T., Yatsuhashi H., Watanabe H., Saitsu H., Nakao K., Taketomi A., Ohta S., Tabaru A., Takenaka K., Mizuta T., Nagata K., Komorizono Y., Fukuizumi K., Seike M., Matsumoto S., Maeshiro T., Tsubouchi H., Muro T., Inoue O., Akahoshi M., Sata M.
Hepatology Research 41 ( 6 ) 564 - 571 2011年6月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Hepatology Research
Aim: Non-hepatitis B virus/non-hepatitis C virus-related hepatocellular carcinoma (NBNC-HCC) is often detected at an advanced stage, and the pathology associated with the staging of NBNC-HCC remains unclear. Data mining is a set of statistical techniques which uncovers interactions and meaningful patterns of factors from a large data collection. The aims of this study were to reveal complex interactions of the risk factors and clinical feature profiling associated with the staging of NBNC-HCC using data mining techniques. Methods: A database was created from 663 patients with NBNC-HCC at 20 institutions. The Milan criteria were used as staging of HCC. Complex associations of variables and clinical feature profiling with the Milan criteria were analyzed by graphical modeling and decision tree algorithm methods, respectively. Results: Graphical modeling identified six factors independently associated with the Milan criteria: diagnostic year of HCC; diagnosis of liver cirrhosis; serum aspartate aminotransferase (AST); alanine aminotransferase (ALT); α-fetoprotein (AFP); and des-γ-carboxy prothrombin (DCP) levels. The decision trees were created with five variables to classify six groups of patients. Sixty-nine percent of the patients were within the Milan criteria, when patients showed an AFP level of 200ng/mL or less, diagnosis of liver cirrhosis and an AST level of less than 93IU/mL. On the other hand, 18% of the patients were within the Milan criteria, when patients showed an AFP level of more than 200ng/mL and ALT level of 20IU/mL or more. Conclusion: Data mining disclosed complex interactions of the risk factors and clinical feature profiling associated with the staging of NBNC-HCC. © 2011 The Japan Society of Hepatology.
-
急性膵炎を来した Henoch-Schonlein 紫斑病の1例
三池 忠, 田原 良博, 山本 章二朗, 橋本 神奈, 山路 卓巳, 安倍 弘生, 楠元 寿典, 蓮池 悟, 永田 賢治, 下田 和哉
日本消化器内視鏡学会雑誌 = Gastroenterological endoscopy 53 ( 5 ) 1465 - 1471 2011年5月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：一般社団法人 日本消化器内視鏡学会
52歳，男性．両側下腿の紫斑，腹痛，血便を呈し，Henoch-Schönlein紫斑病と診断した．膵型優位の血清アミラーゼ，リパーゼの上昇が出現し，腹部CTでは軽度膵腫大を認め，急性膵炎を合併した．ステロイド，メシル酸ガベキサートを投与し，Henoch-Schönlein紫斑病，膵炎ともに軽快した．稀ではあるが，Henoch-Schönlein紫斑病に膵炎を合併することがあり，腹痛の原因として膵炎の可能性を念頭に，素早く適切な対応が必要である．
DOI： 10.11280/gee.53.1465
-
A case of Henoch-Schönlein purpura associated with acute pancreatitis
Miike T., Tahara Y., Yamamoto S., Hashimoto K., Yamaji T., Abe H., Kusumoto K., Hasuike S., Nagata K., Shimoda K.
Gastroenterological Endoscopy 53 ( 5 ) 1465 - 1471 2011年5月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Gastroenterological Endoscopy
A 52 year old man presented with purpura on his lower limbs, abdominal pain, and melena. He was subsequently diagnosed as having Henoch-Schönlein purpura. Two days after admission, he was diagnosed as having acute pancreatitis-related complications based on the elevated serum levels of amylase and lipase, and slight pancreatic enlargement as seen on abdominal CT images. Following administration of predonisolone and gabexate mesylate the acute pancreatitis improved concomitantly with improvement of the Henoch- Schönlein purpura. As regarding the cause of abdominal pain, we should treat pancreatitis rapidly and adequately, because Henoch-Schönlein purpura is rarely associated with acute pancreatitis.
-
Taura N., Fukushima N., Yatsuhashi H., Takami Y., Seike M., Watanabe H., Mizuta T., Sasaki Y., Nagata K., Tabara A., Komorizono Y., Taketomi A., Matsumoto S., Tamai T., Muro T., Nakao K., Fukuizumi K., Maeshiro T., Inoue O., Sata M.
Medical Science Monitor 17 ( 2 ) 2011年2月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Medical Science Monitor
Background: The incidence of hepatocellular carcinoma (HCC) in Japan has still been increasing. The aim of the present study was to analyze the epidemiological trend of HCC in the western area of Japan, Kyushu. Material/Methods: A total of 10,010 patients with HCC diagnosed between 1996 and 2008 in the Liver Cancer study group of Kyushu (LCSK), were recruited for this study. Cohorts of patients with HCC were categorized into five year intervals. The etiology of HCC was categorized to four groups as follows; B: HBsAg positive, HCVRNA negative, C: HCV-RNA positive, HBsAg negative, B+C: both of HBsAg and HCV-RNA positive, non- BC: both of HBsAg and HCV-RNA negative. Results: B was 14.8% (1,485 of 10,010), whereas 68.1% (6,819 of 10,010) had C, and 1.4% (140 of 10,010) had HCC associated with both viruses. The remaining 1,566 patients (15.6%) did not associate with both viruses. Cohorts of patients with HCC were divided into six-year intervals (1996-2001 and 2002-2007). The ratio of C cases decreased from 73.1% in 1996-2001 to 64.9% in 2002-2007. On the other hand, B and -nonBC cases increased significantly from 13.9% and 11.3% in 1996-2001 to 16.2% and 17.6% in 2002-2007, respectively. Conclusions: The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased after 2001 in Kyushu area. This change was due to the increase in the number and proportion of the HCC not only nonBC patients but also B patients. © Med Sci Monit.
-
Automated external defibrillator (AED) の屋外使用時における音声指示の問題点 : 救命できた自験例をふまえて
長田 直人, 宮永 省三, 外山 勝浩, 松田 圭二, 永田 賢治, 新福 玄二, 成尾 浩明, 松田 俊太郎
日本集中治療医学会雑誌 = Journal of the Japanese Society of Intensive Care Medicine 18 ( 1 ) 113 - 114 2011年1月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：The Japanese Society of Intensive Care Medicine
DOI： 10.3918/jsicm.18.113
-
Improvement of rheumatoid arthritis and autoimmune hepatitis in a patient treated with the tumor necrosis factor inhibitor, etanercept.
Umekita K, Miyauchi S, Ueno S, Takajo I, Kusumoto K, Hasuike S, Umekita Y, Tanaka H, Nagata K, Nagatomo Y, Kataoka H, Shimoda K, Okayama A
Internal medicine (Tokyo, Japan) 50 ( 11 ) 1245 - 9 2011年
記述言語：日本語 掲載種別：研究論文（学術雑誌）
-
Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma
KAMEDA T., SHIDE K., SHIMODA H. K., HIDAKA T., KUBUKI Y., KATAYOSE K., TANIGUCHI Y., SEKINE M., KAMIUNNTENN A., MAEDA K., NAGATA K., MATSUNAGA T., SHIMODA K.
International journal of hematology 92 ( 2 ) 320 - 325 2010年9月
記述言語：日本語 掲載種別：研究論文（学術雑誌）
-
血栓性血小板減少性紫斑病との鑑別を要した自己免疫性溶血性貧血合併抗リン脂質抗体症候群
唐澤 直希, 谷口 康博, 日高 智徳, 片寄 恵子, 亀田 拓郎, 幣光 太郎, 下田 晴子, 永田 賢治, 久冨木 庸子, 松永 卓也, 下田 和哉
臨床血液 51 ( 4 ) 275 - 280 2010年4月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：「臨床血液」編集部
-
KANMURA Shuji, UTO Hirofumi, SATO Yuko, KUMAGAI Koutarou, SASAKI Fumisato, MORIUCHI Akihiro, OKETANI Makoto, IDO Akio, NAGATA Kenji, HAYASHI Katsuhiro, STUVER Sherri O., TSUBOUCHI Hirohito
Journal of gastroenterology 45 ( 4 ) 459 - 467 2010年4月
記述言語：日本語 掲載種別：研究論文（学術雑誌）